Ipamorelin
Category 1Last reviewed: April 28, 2026
A selective growth hormone secretagogue that stimulates GH release with minimal effects on cortisol and prolactin. Considered one of the 'cleanest' GH-releasing peptides due to its selectivity.
Mechanism of Action
Binds to ghrelin receptors (GHS-R) in the pituitary gland, triggering pulsatile growth hormone release. Unlike other GH secretagogues, it does not significantly increase cortisol, ACTH, or prolactin levels.
Common Uses
- Growth hormone optimization
- Improved sleep quality
- Fat loss
- Muscle recovery and growth
- Anti-aging protocols
Known Risks
- Headaches
- Water retention
- Tingling sensations
- Limited long-term human data
- May affect blood sugar
Regulatory Status
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
100–300 mcg
Frequency
2–3x daily (before bed is most important dose)
Cycle Length
8–12 weeks on, 4 weeks off
The cleanest GH secretagogue — minimal cortisol/prolactin elevation. Stack with CJC-1295 (no DAC) for synergistic GH release. Inject on empty stomach for best results.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.